RT Journal Article
SR Electronic
T1 High Risk Infants who are Low Dose Tolerant after Peanut Oral Food Challenges
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.01.31.20019570
DO 10.1101/2020.01.31.20019570
A1 Lin, Adora
A1 Uygungil, Burcin
A1 Robbins, Karen
A1 Ackerman, Olivia
A1 Sharma, Hemant
YR 2020
UL http://medrxiv.org/content/early/2020/02/03/2020.01.31.20019570.abstract
AB Background Early peanut (PN) introduction may prevent peanut allergy in at-risk children. Little data exists regarding early introduction for infants with large skin prick tests (SPT) or high peanut IgE levels, who are not often offered oral food challenges (OFC).Objective To retrospectively assess tolerance of a low dose (1 gram) of peanut in infants at risk for peanut allergy, including highest-risk infants (HRI) with SPT wheal >7mm.Methods We reviewed PN OFCs performed over a two-year period at our pediatric allergy center. Low-dose PN OFC was offered to all infants considered at risk for PN allergy, regardless of peanut SPT or IgE results. Dosing was escalated after OFC at home.Results Of infants with SPT wheal <=4 mm (n=30), 29 (97%) were low-dose-tolerant. Of those with SPT >4 mm (n=40), 25 (63%) were low-dose-tolerant, and Ara h2 IgE was significantly lower compared to non-tolerant individuals (median 0.62 versus 6.49 kU/L, p<0.05). Among HRI with SPT >7mm (n=22), 12 (55%) were tolerant, with median SPT 9mm (range 8-11mm), PN-IgE 1.1 kU/L (0.3-10.7 kU/L) and Ara h2 1.6 kU/L (0-9.57 kU/L). Age, sex, race, eczema, and egg sensitization did not affect tolerance regardless of SPT size. After 3-6 months, most infants tolerant at OFC were gradually able to consume larger doses of PN.Conclusion Many infants with PN-SPT >4mm are tolerant of low-dose peanut, and Ara h 2 IgE may be predictive for clinical tolerance among these infants. Low-dose PN-OFC with gradual updosing may help prevent PN allergy in a greater number of at-risk infants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere was no funding source for this project.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNAFAFood allergyFPIESFood protein induced enterocolitis syndromeHRIHighest risk infantsLEAPLearning Early About Peanut AllergyOFCOral food challengePNPeanutSPTSkin prick testADatopic dermatitis